Organon & Co. (NYSE:OGN) Price Target Raised to $8.00 at Barclays

Organon & Co. (NYSE:OGN) had its price target boosted by Barclays from $7.50 to $8.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has an “underweight” rating on the stock. Barclays‘s target price points to a potential downside of 1.28% from the company’s previous close.

Several other analysts have also commented on the company. JPMorgan Chase & Co. cut their price objective on Organon & Co. from $14.00 to $12.00 and set an “underweight” rating for the company in a report on Tuesday, November 11th. Zacks Research cut Organon & Co. from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Wall Street Zen lowered Organon & Co. from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Piper Sandler cut Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 target price for the company. in a research report on Monday, October 27th. Finally, Morgan Stanley lowered their price target on Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and five have assigned a Sell rating to the stock. Based on data from MarketBeat, Organon & Co. has an average rating of “Reduce” and an average price target of $8.50.

Organon & Co. Stock Performance

Shares of NYSE OGN opened at $8.10 on Tuesday. The company has a quick ratio of 1.20, a current ratio of 1.75 and a debt-to-equity ratio of 9.69. The firm’s 50-day moving average price is $7.94 and its 200-day moving average price is $8.51. Organon & Co. has a 52-week low of $6.18 and a 52-week high of $16.18. The company has a market cap of $2.11 billion, a PE ratio of 11.39, a PEG ratio of 0.73 and a beta of 0.58.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings data on Thursday, February 12th. The company reported $0.63 earnings per share for the quarter, missing analysts’ consensus estimates of $0.73 by ($0.10). Organon & Co. had a net margin of 3.01% and a return on equity of 123.06%. The company had revenue of $1.51 billion for the quarter, compared to the consensus estimate of $1.52 billion. During the same quarter last year, the company earned $0.90 EPS. The firm’s revenue for the quarter was down 5.3% on a year-over-year basis. As a group, analysts anticipate that Organon & Co. will post 3.68 EPS for the current year.

Hedge Funds Weigh In On Organon & Co.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. GAMMA Investing LLC lifted its position in shares of Organon & Co. by 22.4% during the third quarter. GAMMA Investing LLC now owns 6,910 shares of the company’s stock valued at $74,000 after buying an additional 1,265 shares during the last quarter. Rexford Capital Inc. lifted its holdings in shares of Organon & Co. by 14.9% during the 3rd quarter. Rexford Capital Inc. now owns 11,380 shares of the company’s stock valued at $122,000 after purchasing an additional 1,480 shares during the last quarter. Amalgamated Bank boosted its position in shares of Organon & Co. by 1.9% in the 3rd quarter. Amalgamated Bank now owns 79,805 shares of the company’s stock worth $852,000 after purchasing an additional 1,514 shares in the last quarter. State of Alaska Department of Revenue increased its position in Organon & Co. by 0.6% during the 4th quarter. State of Alaska Department of Revenue now owns 278,379 shares of the company’s stock valued at $1,995,000 after buying an additional 1,570 shares in the last quarter. Finally, Integrated Wealth Concepts LLC raised its stake in Organon & Co. by 2.8% in the third quarter. Integrated Wealth Concepts LLC now owns 58,648 shares of the company’s stock valued at $626,000 after buying an additional 1,594 shares during the last quarter. 77.43% of the stock is currently owned by institutional investors.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.